Drug intelligence / Profile preview

Aclaim

Development stage: Unknown
Lead developer: Group Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

Aclaim is a specialized remineralizing toothpaste developed by Group Pharmaceuticals, primarily indicated for the management of dentinal hypersensitivity and the restoration of tooth enamel. Its primary active ingredient is nano-hydroxyapatite (n-HAp), a biocompatible mineral that constitutes the majority of human tooth enamel and dentin. Aclaim works by depositing nano-hydroxyapatite particles into open dentinal tubules and onto the enamel surface, effectively sealing the tubules to block pain stimuli and promoting the remineralization of demineralized areas. This biomimetic approach helps restore the structural integrity of the teeth and provides long-lasting relief from sensitivity.

Brand names: Aclaim
Other names: Aclaim Toothpaste

Targets

Exposed dentin and dentinal tubules

Beyond the preview

Go deeper on Aclaim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aclaim.

Explore the full profile